Provided by Tiger Trade Technology Pte. Ltd.

Creative Medical Technology Holdings, Inc.

2.33
+0.01000.43%
Post-market: 2.29-0.0391-1.68%19:51 EDT
Volume:103.03K
Turnover:242.19K
Market Cap:8.61M
PE:-0.92
High:2.43
Open:2.29
Low:2.24
Close:2.32
52wk High:6.25
52wk Low:1.50
Shares:3.70M
Float Shares:3.23M
Volume Ratio:1.57
T/O Rate:3.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5200
EPS(LYR):-2.5200
ROE:-86.47%
ROA:-53.03%
PB:1.15
PE(LYR):-0.92

Loading ...

Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000

Reuters
·
Mar 21

Creative Medical Technology Holdings Inc expected to post a loss of 37 cents a share - Earnings Preview

Reuters
·
Mar 11

BRIEF-Creative Medical Technology Holdings Achieves Second Who Inn Milestone

Reuters
·
Feb 10

Creative Medical Technology Holdings Achieves Second Who Inn Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline

THOMSON REUTERS
·
Feb 10

Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline

Reuters
·
Feb 10

Creative Medical Technology Reports Positive Interim Results for CELZ-201 in Chronic Lower Back Pain Trial

Reuters
·
Jan 13

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

THOMSON REUTERS
·
Jan 13

Creative Medical Technology Holdings Secures Regulatory Approval for Burn Pit Initiative

Reuters
·
Jan 06

Creative Medical Technology Holdings Inc. Held Annual Shareholder Meeting

Reuters
·
Dec 20, 2025

BRIEF-Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial

Reuters
·
Dec 17, 2025

Creative Medical Technology Holdings Completes Enrollment in FDA-Cleared CELZ-201 Trial

Reuters
·
Dec 17, 2025

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for Celz-201-Olastrocel, Marking Major Clinical Inflection Point

THOMSON REUTERS
·
Dec 17, 2025

BRIEF-Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”

Reuters
·
Dec 02, 2025

Creative Medical Technology Holdings Announces World Health Organization Approval of “Olastrocel” as Inn for Lead Allogeneic Cell Therapy Celz-201

THOMSON REUTERS
·
Dec 02, 2025

Creative Medical Technology Holdings Awards CEO $100,000 Bonus and CFO $25,000 Bonus

Reuters
·
Nov 12, 2025

Creative Medical Technology Holdings Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
Nov 05, 2025

Creative Medical Technology Holdings Raises $4.2 Million Through Warrant Exercises and Issues New Warrants

Reuters
·
Nov 01, 2025

Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits

GlobeNewswire
·
Oct 30, 2025

Creative Medical Technology Holdings Inc. Announces Date for Annual Stockholders Meeting

Reuters
·
Oct 30, 2025

Creative Medical announces agreements for warrant exercise for $4.2M proceeds

TIPRANKS
·
Oct 29, 2025